|
Market Cap (6-Jun) $34,684,952 (1,259th) |
Close (30-Jun) $0.080 |
Volume (30-Jun) 244,049 |
Shortsold (15-Jan) 38,875 (0.01%) (540th) |
|
52w High $0.260 |
52w Low $0.056 |
P/E - |
EPS -0.02 |
NSB released this announcement to the ASX on 3 December 2020, 12:54. The announcement is not marked as price sensitive, and is 15 page(s) in length and 289.95kb in size.
You can view all announcements from NSB and see how they appear on a price chart on the announcements page.
At the date of this announcement, NSB was 0.011% short sold according to ASIC data. It was ranked the 585th most shorted stock on the ASX. It is now ranked as the 540th most shorted stock on the ASX with 0.012% of total shares short sold as of the latest reported data (15 January 2026).
| Other Recent Announcements from NSB | |
|---|---|
| Change of Director's Interest Notice - Rennie | 7 June 2023, 8:22 |
| Change of Director's Interest Notice - Uvarov | 25 May 2023, 15:30 |
| Change of Director's Interest Notice - Rennie | 25 May 2023, 15:07 |
| Appendix 2A | 3 December 2020, 12:54 |
| Corporate Governance Statement | 27 November 2020, 15:15 |
| Appendix 4G | 25 November 2020, 18:23 |
| NSB to investigate treatment for post-COVID Fibrosis | 20 November 2020, 10:56 |
You must be logged in to post a reply.
NeuroScientific Biopharmaceuticals 